May 24, 2018
“In biotechnology, if you are not applying digital health solutions to your products and programs, you are not at the cutting edge of transforming healthcare,” says Norma Biln, CEO of Augurex.
Augurex is a commercial-stage biotechnology company that has a blood test (JOINTstat® 14-3-3η) that is helping improve clinical outcomes in patients with Rheumatoid Arthritis through early diagnosis and disease management. Alongside this marketed product and the multiple biomarkers that it has under development in immunology, Augurex sees data-driven, patient-centric care as a critical component for the advancement of all its programs, now and into the future.
Privately held, Augurex began research programs in 2008, focused on a novel biomarker, the 14-3-3η protein. It is involved in the joint damage process, with current applications in rheumatoid arthritis (RA). From this initial basic research, a portfolio of 14-3-3η-centric clinical programs emerged, revealing the potential of this previously unfamiliar factor in autoimmunity and transforming the management of RA.
Augurex credits collaborations with top-tier international scientific and clinical researchers for the successful advancement of 14-3-3η programs. Their guiding principle: to work with experts in their respective areas along the continuum of studies from design to data analysis and publication to address important clinical unmet needs in well-characterized cohorts.
CEO and co-founder Norma Biln, recently recognized as one of BC’s Most Influential Women 2018 and Women’s Executive Network Top 100 Most Powerful Women in Canada, is enthusiastic about the opportunities presented by the Digital Technology Supercluster.
“Consistent with our philosophy of working with world leading experts, Augurex will work alongside Supercluster members like Telus Health, Providence, Microsoft and LifeLabs to expedite the advancement of patient centric mobile health solutions that will drastically improve clinical and economic outcomes.
As a company at the forefront of medical innovation, Augurex is well positioned to help set the direction for the Digital Technology Supercluster and access cutting edge technology and established connectivity to grow within and impact the health ecosystem positioning Canada as a leader in the global innovation race.